▶주메뉴 바로가기
▶본문 바로가기
[THE INVESTOR] Korean drug developer Enzychem Lifesciences ’ upcoming relisting on KOSDAQ is getting strong demand from investors, with the target price range more than doubling in a week, accordi...
[THE INVESTOR] Korea’s biotech firm PharmAbcine said on Jan. 23 it has completed a pre-Investigational New Drug meeting with the US Food and Drug Administration for its lead candidate TTAC0001, pa...
[THE INVESTOR] LG Household & Health Care said on Jan. 23 its net profit increased 6.8 percent in 2017 from a year earlier on steady demand for its luxury cosmetics products from domestic and overse...
[THE INVESTOR] Korean pharmaceutical firm SillaJen said on Jan. 22 that it has signed a manufacturing agreement with France-based ABL Europe to help initiate early-stage studies of its oncolytic v...
[THE INESTOR] GlaxoSmithKline has tapped Julien Samson, a vice president who has been leading the company‘s medicine commercialization for global respiratory franchise, as the new general manager of...
[THE INVESTOR] Celltrion said on Jan. 19 that its net profit soared 82.1 percent in 2017 from a year earlier on robust sales of its biosimilar drug Remsima in overseas markets. Net profit came t...
[ THE INVESTOR ] Korean pharmaceutical firm Celltrion has filed two lawsuits challenging the validity of Genentech’s patents for its blockbuster therapies Herceptin and Rituxan as the Korean compan...
[THE INVESTOR] Braman Investment said on Jan.18 that it has invested 10 billion won (US$9.30 million) in Korean biotech firm Neuracle Science , which develops treatment for neurodegenerative disor...
[THE INVESTOR] Alteogen said on Jan. 17 that it will file an Investigational New Drug application for its biosimilar candidate referencing Regeneron’s blockbuster drug Eylea with the US Food and Dr...
[ THE INVESTOR ] Medtronic said on Jan.15 that it has named Chris Lee, previously president of the Greater China region, as president of Asia-Pacific to manage commercial operations and talent deve...
[THE INVESTOR] Korean biopharmaceutical company GemVax & Kael said on Jan. 15 that it plans to file an Investigational New Drug application for its Alzheimer’s disease therapy candidate with the U...
[ THE INVESTOR ] Samsung BioLogics, which offers pharmaceutical contract development and manufacturing services, said on Jan. 15 that it’s too early to talk about the construction of a fourth produ...
[ THE INVESTOR ] South Korean biopharma company Celltrion will begin preparations to build its first overseas production plant this year and confirm a site for the biologics facility before June, i...
[THE INVESTOR] Celltrion may cut Inflectra’s price in the US to as much as half the price of Johnson & Johnson’s original drug Remicade, the top executive of the firm revealed at a premier investor ...
[THE INVESTOR] Celltrion Chairman Seo Jung-jin said on Jan. 11 that the firm will step up efforts to market biosimilar versions of Humira and Avastin at more competitive prices to beat the original ...
IBK buys second Indonesian bank
SsangYong Motor’s Rexton Sports output to rise by 10,000 units
GM must stay in Korea for at least 10 years: KDB
Focus on root of all problems: Samsung’s Lee Jae-yong
LG set to acquire automotive light maker ZKW for W1.6tr
Mexican food chain On The Border looking for new owner
GM Korea union losing ground following due diligence
Past comes back to haunt Korean Air’s Cho family
April 26, 2018
